3 Inflated Stocks Walking a Fine Line

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. All that said, here are three overhyped stocks that may correct and some you should consider instead.

MasTec (MTZ)

One-Month Return: +20%

Involved in the 1996 Olympic Games MasTec (NYSE:MTZ) is an infrastructure construction company that specializes in the telecommunications, energy, and utility industries.

Why Does MTZ Worry Us?

1. High input costs result in an inferior gross margin of 12.7% that must be offset through higher volumes
2. Operating margin of 3% falls short of the industry average, and the smaller profit dollars make it harder to react to unexpected market developments
3. Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 5.8 percentage points

At $294.60 per share, MasTec trades at 35x forward P/E. If you’re considering MTZ for your portfolio, see our FREE research report to learn more.

Enphase (ENPH)

One-Month Return: +15%

The first company to successfully commercialize the solar micro-inverter, Enphase (NASDAQ:ENPH) manufactures software-driven home energy products.

Why Should You Sell ENPH?

1. Declining unit sales over the past two years suggest it might have to lower prices to accelerate growth
2. 15.2 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
3. Diminishing returns on capital suggest its earlier profit pools are drying up

Enphase’s stock price of $41.96 implies a valuation ratio of 21.1x forward P/E. Dive into our free research report to see why there are better opportunities than ENPH.

RenaissanceRe (RNR)

One-Month Return: +5.7%

Born in Bermuda after the devastating Hurricane Andrew created a crisis in the catastrophe insurance market, RenaissanceRe (NYSE:RNR) provides property, casualty, and specialty reinsurance and insurance solutions to customers worldwide, primarily through intermediaries.

Why Do We Think Twice About RNR?

1. Sales are projected to tank by 12.1% over the next 12 months as demand evaporates
2. Costs have risen faster than its revenue over the last two years, causing its pre-tax profit margin to decline by 2.8 percentage points
3. Performance over the past two years shows its incremental sales were less profitable, as its 3.6% annual earnings per share growth trailed its revenue gains

RenaissanceRe is trading at $300.66 per share, or 1.1x forward P/B. Check out our free in-depth research report to learn more about why RNR doesn’t pass our bar.

Stocks We Like More

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.